Does empagliflozin improve myocardial oxidative stress injury and cardiac fibrosis in diabetic mice?
Empagliflozin shows promise for the prevention and treatment of diabetic cardiomyopathy by reducing myocardial oxidative stress and fibrosis in a preclinical model.
Glycaemic control with empagliflozin significantly ameliorated myocardial oxidative stress injury and cardiac fibrosis in diabetic mice. Taken together, these results indicate that the empagliflozin is a promising agent for the prevention and treatment of diabetic cardiomyopathy.
Li et al. (Sat,) studied this question.